The in vivo experimentation, involving immunocompromised NSG mice and xenogeneic T cell graft, displays a valuable result regarding the differential capacity of CD4+, CD8+ and total TCR-T to control tumor growth. The gene discussed is CD8A; the disease is neoplasm.